Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Perspective Therapeutics (CATX) Enterprise Value (2016 - 2026)

Perspective Therapeutics' Enterprise Value history spans 17 years, with the latest figure at -$487.9 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 28.72% to -$487.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$487.9 million, a 28.72% decrease, with the full-year FY2025 number at -$144.7 million, up 36.22% from a year prior.
  • Enterprise Value hit -$487.9 million in Q1 2026 for Perspective Therapeutics, down from -$144.7 million in the prior quarter.
  • Over the last five years, Enterprise Value for CATX hit a ceiling of -$9.2 million in Q4 2023 and a floor of -$487.9 million in Q1 2026.
  • Historically, Enterprise Value has averaged -$167.9 million across 5 years, with a median of -$144.7 million in 2025.
  • Biggest five-year swings in Enterprise Value: skyrocketed 78.89% in 2023 and later tumbled 2356.33% in 2024.
  • Tracing CATX's Enterprise Value over 5 years: stood at -$43.8 million in 2022, then skyrocketed by 78.89% to -$9.2 million in 2023, then tumbled by 2356.33% to -$226.9 million in 2024, then soared by 36.22% to -$144.7 million in 2025, then tumbled by 237.06% to -$487.9 million in 2026.
  • Business Quant data shows Enterprise Value for CATX at -$487.9 million in Q1 2026, -$144.7 million in Q4 2025, and -$174.1 million in Q3 2025.